HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Highlights Plans For Reinventing Johnson’s Baby, Globalizing Aveeno

This article was originally published in The Rose Sheet

Executive Summary

A planned restage of Johnson’s Baby will “completely reinvent the brand,” says Jorge Mesquita, global chairman of the J&J’s consumer division. Meanwhile, the firm is working to unfetter “captive” regional brands, expanding OGX and Aveeno across the globe while bringing Le Petit Marseillais to North America, among other growth initiatives.

You may also be interested in...



J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth

When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce – investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.

J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth

When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce, investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.

J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth

When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce, investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel